文献速递药物不良反应与药物警戒特殊人群用药

专科药物临床仪表盘用于改善TNF-α抑制剂安全性与依从性监测的开发

Development of a specialty medication clinical dashboard to improve tumor necrosis factor-α inhibitor safety and adherence monitoring.
PubMed 文献 · Am J Health Syst Pharm · 2022-01-01

该质量改进项目于2019年8月至2020年4月开发了针对TNF-α抑制剂的专科药物临床仪表盘,由临床药师与风湿科、消化科和皮肤科专科医生合作设计,数据来自退伍军人事务部企业数据仓库。在431例接受TNF-α抑制剂治疗的患者中,仪表盘识别出304个标志对应223例独特患者(51.7%),包括新发感染、监测实验室检查逾期、关键实验室结果异常、使用两种生物制剂、续方逾期、急诊就诊和住院等。药师可利用该仪表盘改善TNF-α抑制剂治疗的安全性和依从性,但应与协作实践协议联合使用。

要点

  • 仪表盘识别出51.7%的患者存在安全或依从性相关问题。
  • 27%的患者续方逾期,9%监测实验室检查逾期。

核心结论

  • 药师有机会通过专科药物临床仪表盘改善TNF-α抑制剂治疗的安全性和依从性。
  • 仪表盘应与协作实践协议联合使用。

研究设计与样本

  • 质量改进项目,于2019年8月至2020年4月开展。
  • 仪表盘由临床药师与风湿科、消化科和皮肤科专科医生合作设计。
  • 数据查询自退伍军人事务部企业数据仓库。
  • 纳入有TNF-α抑制剂活跃处方或静脉医嘱的患者。
  • 仪表盘标志结果基于单时间点数据。

主要发现

  • 431例接受TNF-α抑制剂治疗的患者中,识别出304个标志对应223例独特患者(51.7%)。
  • 3%的患者有新发感染,9%监测实验室检查逾期,5%有临界实验室结果。
  • 2%使用两种生物制剂,27%续方逾期,6%有急诊就诊,2%有住院。
  • 无患者因心力衰竭加重或新发恶性肿瘤被标记。

临床怎么用

  • 药师可利用仪表盘识别TNF-α抑制剂治疗中安全性和依从性相关问题。
  • 针对被标记患者进行图表审查以识别药师干预机会。
  • 仪表盘应与协作实践协议联合使用以支持干预实施。

局限性

  • 仪表盘标志结果基于单时间点数据。
  • 项目为单中心质量改进项目,结果可能不广泛适用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the development of a pilot specialty medication clinical dashboard targeting tumor necrosis factor (TNF)-α inhibitor therapy. SUMMARY: This was a quality improvement project conducted between August 2019 and April 2020. The dashboard was designed with collaboration between clinical pharmacists and specialty providers in rheumatology, gastroenterology, and dermatology. Data was queried from the Veterans Affairs Corporate Data Warehouse. Patients with an active prescription or intravenous order for a TNF-α inhibitor were included. Dashboard flag criteria focused on TNF-α inhibitor safety and adherence monitoring. Flag results from the dashboard were characterized from data captured at a single time point. For 431 patients on TNF-α inhibitor treatment at the institution, 304 flags corresponding to 223 unique patients (51.7%) were identified on the dashboard: 3% of patients had a new infection, 9% had overdue monitoring laboratory tests, 5% had a critical laboratory result, 2% were on 2 biologic agents, 27% were overdue for a refill, 6% had an emergency department visit, and 2% had an inpatient admission. No patients were flagged for heart failure exacerbation or new malignancy. Seventeen percent of patients were prescribed high-dose etanercept or adalimumab, representing a potential annual cost savings of $302,497 if 50% of these patients had their dose successfully reduced to labeled dosing. Opportunities for pharmacist intervention utilizing the dashboard were identified and characterized through chart review of flagged patients. CONCLUSION: Pharmacists have the opportunity to improve safety and adherence for TNF-α inhibitor therapy through use of a specialty medication clinical dashboard. The dashboard should be used in conjunction with collaborative practice protocols.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Hu AM, Pepin MJ, Hashem MG, et al. Development of a specialty medication clinical dashboard to improve tumor necrosis factor-α inhibitor safety and adherence monitoring. Am J Health Syst Pharm. 2022. PMID: 34864858. doi:10.1093/ajhp/zxab454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。